Which combination of oral glucose-lowering agents after failure of metformin monotherapy in type 2 diabetes?;Quelle combinaison d'antidiabétiques oraux pour contrôler l'hyperglycémie chez un patient diabétique de type 2 insuffisamment équilibré sous metformine?

Revue Medicale de Liege

Volumn 66, Issue 3, 2011, Pages 170-175

  Scheen, A J ^a   Paquot, N ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Combined therapy; DPP 4 inhibitor; Gliptin; Metformin; Pioglitazone; Sulfonylurea; Type 2 diabetes

Indexed keywords

METFORMIN; ORAL ANTIDIABETIC AGENT; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE;

ARTICLE; B LYMPHOCYTE; CELL STRESS; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG TREATMENT FAILURE; HUMAN; LIFESTYLE MODIFICATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT CONTRAINDICATION; DRUG COMBINATION; FEMALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TREATMENT FAILURE;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES; TREATMENT FAILURE;

EID: 79959597460     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Numéro spécial.- Le diabète sucré dans tous ses états. Rev Med Liège, 2005, 60, 269-631.
2. Home P, Mant J, Diaz J, Turner C; Guideline Development Group.- Management of type 2 diabetes : summary of updated NICE guidance. BMJ, 2008, 336, 1306-1308. (Pubitemid 351839637)
3. Rodbard HW, Jellinger PS, Davidson JA, et al.- Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus : an algorithm for glycemic control. Endocr Pract, 2009, 15, 540-559.
4. Nathan DM, Buse JB, Davidson MB, et al.- Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2009, 52, 17-30.
5. Turner RC, Cull CA, Frighi V, Holman RR.- Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA, 1999, 281, 2005-2012.
6. Kahn SE, Haffner SM, Heise MA, et al.- Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med, 2006, 355, 2427-2443. (Pubitemid 44903747)
7. Scheen AJ, Radermecker RP, Philips JC, et al.- Le traitement du diabète de type 2 : entre insulinosensibilisateurs et insulinosécrétagogues. Rev Med Liège, 2007, 62 (numéro spécial Synthèse), 40-46.
8. Philips JC, Scheen AJ.- Inertie clinique dans la prise en charge du patient diabétique de type 2 : quelles solutions proposer ? Rev Med Liège, 2010, 65, 318-325.
9. De Flines J, Radermecker RP, Jandrain B, Scheen AJ.- La vignette thérapeutique de l'étudiant. Optimisation du traitement pharmacologique chez un patient avec un diabète de type 2 nouvellement diagnostiqué. Rev Med Liège, 2009, 64, 103-109.
10. Schernthaner G, Barnett AH, Betteridge DJ, et al.- Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia, 2010, 53, 1258-1269.
11. Smith RJ, Nathan DM, Arslanian SA, et al.- Individualizing therapies in type 2 diabetes mellitus based on patient characteristics : what we know and what we need to know. J Clin Endocrinol Metab, 2010, 95, 1566-1574.
12. Scheen AJ, Paquot N.- Options thérapeutiques pour contrôler l'hyperglycémie chez un patient diabétique de type 2 insuffisamment équilibré sous l'association metformine-sulfamide. Rev Med Liège, 2011, 66, sous presse.
13. UK Prospective Diabetes Study (UKPDS) Group.- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352, 837-853.
14. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al.- Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med, 2008, 358, 2560-2572.
15. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA.- Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? : a meta-analysis of observational studies. Diabetes Care, 2008, 31, 1672-1678.
16. Radermecker RP.- Le risque hypoglycémique chez le patient diabétique : implications thérapeutiques. Rev Med Liège, 2005, 60, 461-465.
17. Home PD, Pocock SJ, Beck-Nielsen H, et al.- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD) : a multicentre, randomised, open-label trial. Lancet, 2009, 373, 2125-2135.
18. Scheen AJ, Radermecker RP.- Addition of incretin therapy to metformin in type 2 diabetes. Lancet, 2010, 375, 1410-1412.
19. Scheen AJ, Van Gaal LF.- Sitagliptine (Januvia®) . Incrétinopotentiateur indiqué comme insulinosécré tagogue dans le traitement du diabète de type 2. Rev Med Liège, 2008, 63, 105-109. (Pubitemid 351437928)
20. Scheen AJ, Paquot N.- Vildagliptine (Galvus®) et combinaison fixe vildagliptine-metformine (Eucreas®), dans le traitement du diabète de type 2. Rev Med Liège, 2009, 64, 161-167.
21. Scheen AJ.- Saxagliptine (Onglyza®) : nouvel inhibiteur de la dipeptidylpeptidase-4 pour le traitement oral du diabète de type 2. Rev Med Liège, 2010, 65, 527-532.
22. Scheen AJ.- Le glucagon-like peptide-1 (GLP-1), nouvelle cible dans le traitement du diabète de type 2. Rev Med Liège, 2007, 62, 216-219.
23. Monami M, Iacomelli I, Marchionni N, Mannucci E.- Dipeptidyl peptidase-4 inhibitors in type 2 diabetes : a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis, 2010, 20, 224-235.
24. Scheen AJ, Lefèbvre PJ.- L'étude PROactive : prévention secondaire des accidents cardio-vasculaires par la pioglitazone chez le patient diabétique de type 2. Rev Med Liège, 2005, 60, 896-901. (Pubitemid 43001235)
25. Scheen AJ, De Flines J, Paquot N.- Le point sur la controverse à propos de la rosiglitazone. Rev Med Liège, 2007, 62, 560-565. (Pubitemid 351448307)
26. Tzoulaki I, Molokhia M, Curcin V, et al.- Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ, 2009, 339, b4731. doi: 10.1136/bmj.b4731.
27. Scheen AJ.- Suspension de la commercialisation de la sibutramine et de la rosiglitazone en Europe. Rev Med Liège, 2010, 65, 574-579.
28. Scheen AJ, Tan MH, Betteridge DJ, et al.- Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18). Diabet Med, 2009, 26, 1242-1249.
29. De Flines J, Scheen AJ.- Glitazones et insuffisance cardiaque : résultats des études PROactive, ADOPT, DREAM et RECORD. Rev Med Suisse, 2007, 3, 1876-1883. (Pubitemid 47425206)
30. Bilik D, McEwen LN, Brown MB, et al.- Thiazolidinediones and fractures : evidence from translating research into action for diabetes. J Clin Endocrinol Metab, 2010, 95, 4560-4565.
31. Scheen AJ.- Glitazones et prise de poids. Ann Endocrinol, 2002, 63, 1S41-44.
32. Scheen AJ, Charpentier G, Ostgren CJ, et al.- Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev, 2010, 26, 540-549.
33. Scheen AJ, Van Gaal LF.- SUGAR : résultats d'une étude observationnelle belge concernant l'utilisation de la sitagliptine chez des patients diabétiques de type 2. Rev Med Liège, 2010, 65, 127-132.
34. Scheen AJ.- Combinaison fixe sitagliptine-metformine (Janumet®) . Rev Med Liège, 2010, 65, 648-654.
35. Scheen AJ.- Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Exp Opin Drug Metab Toxicol, 2010, 6, 1265-1276.
36. Paquot N.- Effets néfastes du défaut d'observance hygiéno-diététique et médicamenteuse chez le patient diabétique. Rev Med Liège, 2010, 65, 326-331.